Reuters logo
Elan board unanimously rejects Royalty Pharma bid
April 22, 2013 / 5:16 AM / 5 years ago

Elan board unanimously rejects Royalty Pharma bid

DUBLIN, April 22 (Reuters) - The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S. investment firm’s offer of $11.25 a share grossly undervalues the company.

Royalty launched a cash offer a week ago worth up to $7.3 billion, or $12 per Elan share, improving on an initial proposal to take over the Dublin-based company and the lucrative royalty rights on its main drug.

That offer depended on the outcome of a $1 billion share buyback conducted by Elan last week. Royalty lowered the bid to $11.25 a share as a result of the pricing of the buyback.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below